Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

Mario Cottone, Mario Cottone, Irene Modesto, Sara Renna, Ambrogio Orlando

Risultato della ricerca: Article

13 Citazioni (Scopus)

Abstract

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in theinduction and maintenance of remission of mild-to-moderate ulcerative colitis(UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. Thenew delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMXformulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the groupgiven the once daily regimen, compared with the classic twice daily groups.Regarding the efficacy of alternative treatment such us probiotics andantibiotics, the current data are not sufficient to promote their use in clinicalpractice. Clinical evidence supports the use of topical 5-ASA in active mild tomoderate distal UC showing superior efficacy to placebo, topical corticosteroids, and oral 5-ASA. A combination of oral and rectal 5-ASA produces additionalefficacy in both limited and extensive UC. Topical 5-ASA formulations areeffective also for the maintenance of remission, however long term treatment may not be acceptable to many patients. Other topical drugs (E. Coli Nissle,propionyl-L-carnitine, butyrate, tacrolimus, rosiglitazone) have beeninvestigated with conflicting results. The possible chemopreventive role of long term treatment with 5-ASA strengthens the indication to the long term use of5-ASA.
Lingua originaleEnglish
pagine (da-a)1396-1405
Numero di pagine10
RivistaCurrent Drug Targets
Volume12
Stato di pubblicazionePublished - 2011

Fingerprint

Ulcerative Colitis
Amino Acids
propionylcarnitine
rosiglitazone
Maintenance
Therapeutics
Sulfasalazine
Carnitine
Butyrates
Probiotics
Tacrolimus
Escherichia coli
Compliance
Adrenal Cortex Hormones
Placebos
Safety
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cita questo

Cottone, M., Cottone, M., Modesto, I., Renna, S., & Orlando, A. (2011). Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis? Current Drug Targets, 12, 1396-1405.

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis? / Cottone, Mario; Cottone, Mario; Modesto, Irene; Renna, Sara; Orlando, Ambrogio.

In: Current Drug Targets, Vol. 12, 2011, pag. 1396-1405.

Risultato della ricerca: Article

Cottone, M, Cottone, M, Modesto, I, Renna, S & Orlando, A 2011, 'Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?', Current Drug Targets, vol. 12, pagg. 1396-1405.
Cottone M, Cottone M, Modesto I, Renna S, Orlando A. Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis? Current Drug Targets. 2011;12:1396-1405.
Cottone, Mario ; Cottone, Mario ; Modesto, Irene ; Renna, Sara ; Orlando, Ambrogio. / Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?. In: Current Drug Targets. 2011 ; Vol. 12. pagg. 1396-1405.
@article{54fc5845590547bb8da977f3bc1a7b0d,
title = "Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?",
abstract = "5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in theinduction and maintenance of remission of mild-to-moderate ulcerative colitis(UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. Thenew delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMXformulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the groupgiven the once daily regimen, compared with the classic twice daily groups.Regarding the efficacy of alternative treatment such us probiotics andantibiotics, the current data are not sufficient to promote their use in clinicalpractice. Clinical evidence supports the use of topical 5-ASA in active mild tomoderate distal UC showing superior efficacy to placebo, topical corticosteroids, and oral 5-ASA. A combination of oral and rectal 5-ASA produces additionalefficacy in both limited and extensive UC. Topical 5-ASA formulations areeffective also for the maintenance of remission, however long term treatment may not be acceptable to many patients. Other topical drugs (E. Coli Nissle,propionyl-L-carnitine, butyrate, tacrolimus, rosiglitazone) have beeninvestigated with conflicting results. The possible chemopreventive role of long term treatment with 5-ASA strengthens the indication to the long term use of5-ASA.",
keywords = "5-ASA, Choice, Colitis, Treatment, Ulcerative",
author = "Mario Cottone and Mario Cottone and Irene Modesto and Sara Renna and Ambrogio Orlando",
year = "2011",
language = "English",
volume = "12",
pages = "1396--1405",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

AU - Cottone, Mario

AU - Cottone, Mario

AU - Modesto, Irene

AU - Renna, Sara

AU - Orlando, Ambrogio

PY - 2011

Y1 - 2011

N2 - 5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in theinduction and maintenance of remission of mild-to-moderate ulcerative colitis(UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. Thenew delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMXformulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the groupgiven the once daily regimen, compared with the classic twice daily groups.Regarding the efficacy of alternative treatment such us probiotics andantibiotics, the current data are not sufficient to promote their use in clinicalpractice. Clinical evidence supports the use of topical 5-ASA in active mild tomoderate distal UC showing superior efficacy to placebo, topical corticosteroids, and oral 5-ASA. A combination of oral and rectal 5-ASA produces additionalefficacy in both limited and extensive UC. Topical 5-ASA formulations areeffective also for the maintenance of remission, however long term treatment may not be acceptable to many patients. Other topical drugs (E. Coli Nissle,propionyl-L-carnitine, butyrate, tacrolimus, rosiglitazone) have beeninvestigated with conflicting results. The possible chemopreventive role of long term treatment with 5-ASA strengthens the indication to the long term use of5-ASA.

AB - 5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in theinduction and maintenance of remission of mild-to-moderate ulcerative colitis(UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. Thenew delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMXformulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the groupgiven the once daily regimen, compared with the classic twice daily groups.Regarding the efficacy of alternative treatment such us probiotics andantibiotics, the current data are not sufficient to promote their use in clinicalpractice. Clinical evidence supports the use of topical 5-ASA in active mild tomoderate distal UC showing superior efficacy to placebo, topical corticosteroids, and oral 5-ASA. A combination of oral and rectal 5-ASA produces additionalefficacy in both limited and extensive UC. Topical 5-ASA formulations areeffective also for the maintenance of remission, however long term treatment may not be acceptable to many patients. Other topical drugs (E. Coli Nissle,propionyl-L-carnitine, butyrate, tacrolimus, rosiglitazone) have beeninvestigated with conflicting results. The possible chemopreventive role of long term treatment with 5-ASA strengthens the indication to the long term use of5-ASA.

KW - 5-ASA

KW - Choice

KW - Colitis

KW - Treatment

KW - Ulcerative

UR - http://hdl.handle.net/10447/59275

M3 - Article

VL - 12

SP - 1396

EP - 1405

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

ER -